An approach for the transition from systemic immunosuppressants to dupilumab.

de Wijs, L E M; Thyssen, J P; Vestergaard, C; Thio, H B; Kunkeler, A C M; Biedermann, T; Hijnen, D J

de Wijs, L E M; Thyssen, J P; Vestergaard, C; Thio, H B; Kunkeler, A C M; Biedermann, T; Hijnen, D J.

Affiliation

de Wijs LEM; Department of Dermatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands.
Thyssen JP; Department of Dermatology and Allergy, Herlev-Gentofte Hospital, University of Copenhagen, Denmark.
Vestergaard C; Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark.
Thio HB; Department of Dermatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands.
Kunkeler ACM; Department of Dermatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands.
Biedermann T; Department of Dermatology and Allergy, Technical University of Munich, Munich, Germany.
Hijnen DJ; Department of Dermatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands.

J Eur Acad Dermatol Venereol ; 35(3): e221-e223, 2021 Mar.

Article in En | MEDLINE | ID: mdl-32920932

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Dermatitis, Atopic / Immunosuppressive Agents Limits: Humans Language: En Journal: J Eur Acad Dermatol Venereol Journal subject: DERMATOLOGIA / DOENCAS SEXUALMENTE TRANSMISSIVEIS Year: 2021 Document type: Article Affiliation country: Países Bajos Country of publication: Reino Unido

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google